By Mariam Sunny and Michael Erman Feb 13 (Reuters) - Moderna said it is looking for growth overseas after the U.S. FDA ...

Here are some of the biggest movers in midday trading. Moderna – Shares of the biotech giant climbed 5% after the company ...

Moderna will report its fourth-quarter 2025 earnings this morning in an investor call that’s taken on even more interest in ...

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...

Thank you, Kevin. Good morning, everyone, and thank you for joining us on today’s call to discuss Moderna, Inc.’s fourth quarter 2025 financial results and business update. On today’s call are ...

Q4 2025 earnings call highlights: revenue, cost cuts, cash outlook, FDA flu setback, and 2026 growth guidance—read key insights now.

In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.

MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.

Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.